TP53 in MDS and AML: Biological and clinical advances

待确认 10 由 111 发布于 2026/2/2 6:43:01

DOI:10.1016/j.canlet.2024.216767
作者：Yeqian Zhao ,?Weihao Chen ,?Jing Yu ,?Shanshan Pei ,?Qiang Zhang ,?Jimin Shi ,?He Huang ,?Yanmin Zhao
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：Recently, the WHO-5 and the ICC 2022 criteria have emphasized poor prognosis in AML/MDS patients with multi-hit TP53 mutations, whereas mutated TP53 plays a critical role in tumorigenesis, d

应助信息

等待求助人确认

求助人未确认前，本求助不能再次应助。36小时后系统将自动确认应助成功。本求助将自动关闭。

2小时前

yiqiang

27327c53ffc811f0a28834735aa3bc31.pdf

3小时前

Book学术机器人

2026/2/2 6:43:01 未找到该文献，机器人已退出，请等待人工下载

2026/2/2 6:43:01 Book学术AI机器人收到请求，开始寻找文献

2026/2/2 6:43:01 已向机器人发送请求

3小时前

111 发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:Taylor & FrancisEmerging therapeutic and cosmeceutical applications of phenylalanine and its metabolites.